At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 3 enrolled
Drug / intervention
regorafenib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Single Agent Regorafenib in Patients With Advanced/Metastatic Neuroendocrine Tumors
In Brief
A Phase 2 clinical trial evaluating regorafenib and laboratory biomarker analysis for Gastrinoma and 8 related conditions. Completed, enrolled 3 participants across 5 sites.
Detailed Summary
This phase II trial studies regorafenib in treating patients with neuroendocrine tumors that have spread from the primary site (place where it started) to other places in the body. Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Pancreatic Polypeptide Tumor, Pulmonary Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartAug 2016
Primary CompletionAug 2020
TodayJul 2026
First PostedOct 8, 2014
Enrollment StartAug 16, 2016
Primary CompletionAug 20, 2020
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 11.7 years ago
Interventions
regorafenibdrug
Given PO
laboratory biomarker analysisother
Correlative studies